SEWON Cellontech Co., Ltd.
Tissue engineering, cord blood cell banking, ACT, biomaterials
SEWON Cellontech Co., Ltd. was registred in 2000 and a cell therapy factory and a cord blood bank were established. Chondron® was approved by the Korean Food and Drug Administration (KFDA) in 2001 as the first biotechnology product in Korea. Good Manufacturing Practice was aquired. In the same year SEWON Cellontech became a venture company. In 2002, AusBio (Australia) and CellonTech signed an agreement in relation to Chondron®.
Dong-sam Seo, Dr., CEO
Cheong-Ho Chang, Chairman
10,11th Fl, Goodmorning-shinhan Tower
23-2 Yoido-Dong,
Youngdeungpo-gu,
Seoul, 150-712,
Korea
Phone: +82-02-2167-9000
Fax: +82-02-2167-9157
Today, SEWON Cellontech’s main business areas include cell therapy engineering, cell and tissue bank engineering and biomaterial engineering.SEWON Cellontech’s research centre deals with issues such as mesenchymal stem cells (MSC), haematopoetic stem cells (HSC), nano biomaterials and medical sciences.
The leading products in the field of cell therapy engineering are: Chondron®: autologous in vitro cultured chondrocytes for autologous chondrocyte transplantation (ACT); it is used to stimulate the growth of the patients own cartilage cells.
Ostem®, for autologous osteoblast transplantation, is pending for KFDA approval; Hemstem®, Dendron®, Derman® are designed for autologous and allogenic haematopoetic stem cell, dendric cell and skin transplantation.
In the business area Cell & Tissue Bank Engineering Cellontech offers two programmes: The “Baby Cell Program” is a cord blood banking system and the “Allo Tissue Program” is a bank for allogeneic tissues.
Biomaterial engineering products include Theracol® (pending for KFDA approval), a collagen matrix product in order to accelerate the healing of tissue defects, and Joint Joy®, a glucosamine juice for arthritis patients.
The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.
Related patents
- A Composition for Cartilage Therapeutics and Using Method Thereof
- Simple Method of Tranplanting Injectable Chondrocyte for Autologous Chondrocyte Transplantation
- A Composition for Cartilage Therapeutics and Using Method Thereof
- Manufactured Product Using and Collagen Solution Manufacturing Method and Collagen Separation Method of Animal Tissue
- Artificial Culture of Osteoblast
- Assaying Method of Activity of Osteoblast
- Blood Bag for Separating Eucaryote Cells and Method for Separating Eucaryote Cells Using the Same
- A Composition for Cartilage Therapeutics and a Using Method Thereof
- The Thawing Connective Instrument and Thawing Method for Cryopreserved Umbilical Cord Blood Cells Using the Thawing Connective Instrument
- Bone Formation Composition Composed of Mixture of Osteoblast and Bio-Matrix and Its Manufacturing Method
- Osteoblast Composition of Semi-Solidified Mixed Fibrin for Bone Fracture Agglutination and Its Manufacturing Method
- Semi-solid Gel Composition for Adipose Tissue Regeneration